FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255664349> ?p ?o ?g. }

• W4255664349 abstract "Abstract Background: Clinical trials have suggested high-risk (T4 and/or N2) and low-risk (T1-T3 and N1) stage III colon cancer patients might need different doses of FOLFOX to reserve a similar survival probability. Observational studies have investigated the effect of relative dose intensity (RDI) of FOLFOX on cancer survival for patients with stage III colon cancer, but nonetheless, the studies focused on very specific populations, and none performed stratified analysis by risk profiles. This study aims to identify the optimal RDI of FOLFOX administered for high-risk and low-risk stage III colon cancer patients. Methods: Data on 407 eligible patients, diagnosed with stage III colon cancer in 2011 who received FOLFOX, were collected by the eight population-based cancer registries for a CDC National Program of Cancer Registries (NPCR) project focused on Comparative Effectiveness Research. We employed Kaplan-Meier method, cumulative incidence function (CIF), Multivariable Cox model and Fine-Gray competing risks model to explore Optimal RDI defined as the lowest RDI administered without significant differences in either overall or cause-specific death. Results: Among the 168 high-risk patients, the optimal RDI cut-off point was 70% where there was no statistically significant difference in overall mortality (HR=1.59; 95% CI: 0.69-3.66) and cause-specific mortality (HR=1.24; 95% CI: 0.42-3.64) when RDI<70% vs. RDI≥70%, adjusting for sociodemographic and clinical covariates. When the RDI cut-off was lower than the optimal one (<55% vs. ≥55%, <60% vs. ≥60%, or <65% vs. ≥65%), the overall mortality was significantly statistically different between the two groups of each comparison. Among the 239 low-risk patients, none of the evaluated cut-offs were associated with statistically significant differences in overall and cause-specific mortalities between comparison groups. The lowest RDI we assessed was 45%, HR=0.80; 95% CI: 0.24-2.73 for the overall mortality and HR=0.53; 95% CI: 0.06-4.95 for the cause-specific mortality, when RDI<45% vs. RDI≥45%. Conclusions: To best utilize health care resources while maintaining efficacy, RDI can be maintained at a minimum of 70% for high-risk stage III colon cancer patients. For low-risk patients, we found that RDI as low as 45% did not significantly affect the risk of death." @default.
• W4255664349 created "2022-05-12" @default.
• W4255664349 creator A5006144086 @default.
• W4255664349 creator A5032526995 @default.
• W4255664349 creator A5033529754 @default.
• W4255664349 creator A5039504348 @default.
• W4255664349 creator A5043674257 @default.
• W4255664349 creator A5044757881 @default.
• W4255664349 creator A5046021979 @default.
• W4255664349 creator A5050154595 @default.
• W4255664349 creator A5075691677 @default.
• W4255664349 creator A5080790316 @default.
• W4255664349 date "2020-04-10" @default.
• W4255664349 modified "2023-09-25" @default.
• W4255664349 title "Impact of relative dose intensity of FOLFOX adjuvant chemotherapy on risk of death among stage III colon cancer patients" @default.
• W4255664349 doi "https://doi.org/10.21203/rs.2.20511/v2" @default.
• W4255664349 hasPublicationYear "2020" @default.
• W4255664349 type Work @default.
• W4255664349 citedByCount "0" @default.
• W4255664349 crossrefType "posted-content" @default.
• W4255664349 hasAuthorship W4255664349A5006144086 @default.
• W4255664349 hasAuthorship W4255664349A5032526995 @default.
• W4255664349 hasAuthorship W4255664349A5033529754 @default.
• W4255664349 hasAuthorship W4255664349A5039504348 @default.
• W4255664349 hasAuthorship W4255664349A5043674257 @default.
• W4255664349 hasAuthorship W4255664349A5044757881 @default.
• W4255664349 hasAuthorship W4255664349A5046021979 @default.
• W4255664349 hasAuthorship W4255664349A5050154595 @default.
• W4255664349 hasAuthorship W4255664349A5075691677 @default.
• W4255664349 hasAuthorship W4255664349A5080790316 @default.
• W4255664349 hasBestOaLocation W42556643491 @default.
• W4255664349 hasConcept C121608353 @default.
• W4255664349 hasConcept C126322002 @default.
• W4255664349 hasConcept C143998085 @default.
• W4255664349 hasConcept C146357865 @default.
• W4255664349 hasConcept C151730666 @default.
• W4255664349 hasConcept C2778260052 @default.
• W4255664349 hasConcept C2780962732 @default.
• W4255664349 hasConcept C2908647359 @default.
• W4255664349 hasConcept C44249647 @default.
• W4255664349 hasConcept C50382708 @default.
• W4255664349 hasConcept C526805850 @default.
• W4255664349 hasConcept C71924100 @default.
• W4255664349 hasConcept C82789193 @default.
• W4255664349 hasConcept C86803240 @default.
• W4255664349 hasConcept C99454951 @default.
• W4255664349 hasConceptScore W4255664349C121608353 @default.
• W4255664349 hasConceptScore W4255664349C126322002 @default.
• W4255664349 hasConceptScore W4255664349C143998085 @default.
• W4255664349 hasConceptScore W4255664349C146357865 @default.
• W4255664349 hasConceptScore W4255664349C151730666 @default.
• W4255664349 hasConceptScore W4255664349C2778260052 @default.
• W4255664349 hasConceptScore W4255664349C2780962732 @default.
• W4255664349 hasConceptScore W4255664349C2908647359 @default.
• W4255664349 hasConceptScore W4255664349C44249647 @default.
• W4255664349 hasConceptScore W4255664349C50382708 @default.
• W4255664349 hasConceptScore W4255664349C526805850 @default.
• W4255664349 hasConceptScore W4255664349C71924100 @default.
• W4255664349 hasConceptScore W4255664349C82789193 @default.
• W4255664349 hasConceptScore W4255664349C86803240 @default.
• W4255664349 hasConceptScore W4255664349C99454951 @default.
• W4255664349 hasLocation W42556643491 @default.
• W4255664349 hasLocation W42556643492 @default.
• W4255664349 hasOpenAccess W4255664349 @default.
• W4255664349 hasPrimaryLocation W42556643491 @default.
• W4255664349 hasRelatedWork W1864709827 @default.
• W4255664349 hasRelatedWork W2231220255 @default.
• W4255664349 hasRelatedWork W2232523619 @default.
• W4255664349 hasRelatedWork W2242828348 @default.
• W4255664349 hasRelatedWork W2562908937 @default.
• W4255664349 hasRelatedWork W2808934676 @default.
• W4255664349 hasRelatedWork W2905152986 @default.
• W4255664349 hasRelatedWork W2953872710 @default.
• W4255664349 hasRelatedWork W3029362961 @default.
• W4255664349 hasRelatedWork W3096616336 @default.
• W4255664349 isParatext "false" @default.
• W4255664349 isRetracted "false" @default.
• W4255664349 workType "article" @default.